efineptakin alfa

Home
Ligands
efineptakin alfa

GtoPdb Ligand ID: 11097

Compound class: Peptide or derivative

Comment: Efineptakin alfa is a long-acting immunoglobulin (Ig) fusion protein composed of recombinant human IL-7 fused to a hybrid Fc (hyFc) region of a human antibody. It comprises two disulphide bond-linked peptide chains. Efineptakin alfa has hematopoietic and immunopotentiating activities. In the oncology setting IL-7 enhances T-cell-mediated anti-tumour immune responses. Efineptakin alfa is being developed by Genexine (in-licensed to I-MAB Biopharma) and NeoImmuneTech. The peptide sequence of efineptakin alfa is claimed in Genexine's patent WO2016200219A1 as sequence 24 and would appear to be referred to as MGM-IL-7-hyFc therein [3].

References
1. EMA. IL-7 Fc Orphan designation. Accessed on 17/04/2019. Modified on 17/04/2019. EMA, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171875
2. FDA. IL-7 Fc orphan designation. Accessed on 17/04/2019. Modified on 17/04/2019. FDA, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=666218
3. Yang SH, Choi D, Lim HS. (2016) Modified interleukin-7 protein and uses thereof. Patent number: WO2016200219A1. Assignee: Genexine, Inc.. Priority date: 11/06/2015. Publication date: 15/12/2016.

References

1. EMA.
IL-7 Fc Orphan designation.
Accessed on 17/04/2019. Modified on 17/04/2019. EMA, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171875

2. FDA.
IL-7 Fc orphan designation.
Accessed on 17/04/2019. Modified on 17/04/2019. FDA, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=666218

3. Yang SH, Choi D, Lim HS. (2016)
Modified interleukin-7 protein and uses thereof.
Patent number: WO2016200219A1. Assignee: Genexine, Inc.. Priority date: 11/06/2015. Publication date: 15/12/2016.